Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents

References

• Harrington PM, Woodman C, Shannon WF. Vaccine, yes; injection, no: maternal responses to the introduction of Haemophilus influenzae type b (Hib) vaccine. Br J Gen Pract 1999; 49:901-2; PMID:10818657
   PubMed Web of Science ®Google Scholar
• Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, Young PM, Lee PW, Ngan HY. Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect 2008; 84:227-32; PMID:18256106; http://dx.doi.org/10.1136/sti.2007.029363
   PubMed Web of Science ®Google Scholar
• Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003; 68:341-4; PMID:12685642
   PubMed Web of Science ®Google Scholar
• Francois G, Duclos P, Margolis H, Lavanchy D, Siegrist CA, Meheus A, Lambert PH, Emiroglu N, Badur S, Van Damme P. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J 2005; 24:953-61; PMID:16282928; http://dx.doi.org/10.1097/01.inf.0000183853.16113.a6
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Swan A, Adegbenro A, Ludington SL, Wollan PC, Poland GA. Making vaccines more acceptable – methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 2001; 19:2418-27; PMID:11257372; http://dx.doi.org/10.1016/S0264-410X(00)00466-7
   PubMed Web of Science ®Google Scholar
• Meyerhoff AS, Weniger BG, Jacobs RJ. Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J 2001; 20:S57-62; PMID:11704725; http://dx.doi.org/10.1097/00006454-200111001-00009
   PubMedGoogle Scholar
• Cook IF. Evidence based route of administration of vaccines. Hum Vaccine 2008; 4:67-73; PMID:17881890; http://dx.doi.org/10.4161/hv.4.1.4747
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Vaccine injection technique and reactogenicity–evidence for practice. Vaccine 2008; 26:6299-304; PMID:18804137
   PubMed Web of Science ®Google Scholar
• Hosking J, Rasanathan K, Mow FC, Jackson C, Martin D, O'Hallahan J, Oster P, Ypma E, Reid S, Aaberge I, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol 2007; 14:1393-9; PMID:17898183; http://dx.doi.org/10.1128/CVI.00167-07
   PubMed Web of Science ®Google Scholar
• Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006; 24:1395-400; PMID:16242221; http://dx.doi.org/10.1016/j.vaccine.2005.09.043
   PubMed Web of Science ®Google Scholar
• Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16–24 months. Pediatr Infect Dis J 2007; 26:345-50; PMID:17414400; http://dx.doi.org/10.1097/01.inf.0000258697.05341.2c
   PubMed Web of Science ®Google Scholar
• Jackson C, Lennon DR, Sotutu VT, Yan J, Stewart JM, Reid S, Crengle S, Oster P, Ypma E, Aaberge I, et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child 2009; 94:745-51; PMID:18838420; http://dx.doi.org/10.1136/adc.2007.132571
   PubMed Web of Science ®Google Scholar
• Rahim-Williams B, Riley JL, Williams AKK, Fillingim RB. A quantitative review of ethnic group differences in experimental pain response: do biology, psychology, and culture matter? Pain Med 2012; 13:522-40; PMID:22390201; http://dx.doi.org/10.1111/j.1526-4637.2012.01336.x
   PubMed Web of Science ®Google Scholar
• Christy C, Pichichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, Englund JA, Edwards KM, Steinhoff MC. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96:584-7; PMID:7659481
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Immunisation Handbook 2002. Wellington: Ministry of Health; 2002.
   Google Scholar
• Greenberg DP, Doemland M, Bettinger JA, Scheifele DW, Halperin SA, Waters V, Kandola K, for the II. Epidemiology of pertussis and haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J 2009; 28:521-8; PMID:19436236; http://dx.doi.org/10.1097/INF.0b013e318199d2fc
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB(TM): a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6; PMID:15755593; http://dx.doi.org/10.1016/j.vaccine.2005.01.063
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37; PMID:20954968; http://dx.doi.org/10.1086/656741
   PubMed Web of Science ®Google Scholar